Business Update / Strategic Collaboration
OneSource Highlights Role in Dr. Reddy’s Semaglutide Approval as Manufacturing Partner
NSE
onesource
BSE
544292
OneSource Specialty Pharma announced that it is the manufacturing partner for Dr. Reddy’s generic Semaglutide Injection, which has received Health Canada approval. The company will provide scale-up and commercial manufacturing support, strengthening its CDMO positioning
PRICE-SENSITIVE TRIGGER
Event: Partner Product Approval (Dr. Reddy’s – Semaglutide)
Type: Business Update / Strategic Collaboration
Impact: Positive
Immediate Effect: Reinforces OneSource’s role in high-value CDMO partnerships and enhances visibility in regulated markets, though indirect financial impact
What Happened ?
OneSource Specialty Pharma Limited announced that its partner, Dr. Reddy’s Laboratories, has received Health Canada approval for generic Semaglutide Injection.
OneSource acts as the CDMO (Contract Development and Manufacturing Organization) partner for this program, handling scale-up and commercial manufacturing of the formulation.
key highlights
Strategic Partnership & Manufacturing Role:
- Partner: Dr. Reddy’s Laboratories
- Product: Generic Semaglutide Injection (GLP-1 therapy)
- Regulatory approval: Health Canada (Canada market)
- OneSource role:
- CDMO partner
- Scale-up manufacturing
- Commercial production support
- Manufacturing base: US-FDA approved Bengaluru facility
- Focus on ensuring reliable and scalable supply
- Strengthens collaboration in complex peptide-based therapeutics
Note:
CDMO participation in successful global approvals enhances credibility and future deal pipeline for companies like OneSource.
Risk Analysis
Key Risks
- Dependency on partner (Dr. Reddy’s) for commercialization success
- Margin visibility unclear due to contract structure
- Regulatory compliance for ongoing manufacturing
- Competition in CDMO space
Worst Case Scenario
- If commercialization volumes remain low or partnership scope is limited, financial benefits to OneSource may be minimal.
Risk Level: Medium
Company Commentary
- Acting as CDMO partner for Semaglutide program
- Provides scale-up and commercial manufacturing support
- Strengthens collaboration with Dr. Reddy’s
- Highlights capability in complex generics and peptide manufacturing
- Focus on reliable and scalable supply from advanced facilities
Official Exchange Filing: OneSource Specialty Pharma Limited